RxDoctor Payments Data

Michelle Zetoony Nudell, DO

Internal Medicine · Pinellas Park, FLNPI 1679785364

Payments from drug & device makers

$7,304in general payments, 2019–2025

Across 76 payments — averaging $96.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$5K
  • Harmony Biosciences LLC$2K
  • Avadel CNS Pharmaceuticals, LLC$316
  • AstraZeneca$239
  • Actelion Pharmaceuticals US, Inc.$77
  • Eisai Inc.$68
  • plus $166 from 8 others

What the payments were for

  • Consulting fees$5,52576%
  • Travel & lodging$130%
  • Food & beverage$1,20817%
  • Education$5598%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,304 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$121,669
Medicare patients
678
Services billed
1,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate19$323,396
LumryzSodium Oxybate22$295,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$88,772
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$44,417
Spiriva RespimatTiotropium Bromide35$37,803
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$33,348
HorizantGabapentin Enacarbil20$23,187
NeuproRotigotine17$19,433
Breo ElliptaFluticasone/Vilanterol22$15,984
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$15,217
BelsomraSuvorexant22$11,334
Arnuity ElliptaFluticasone Furoate15$6,807
Modafinil44$5,550
Gabapentin208$3,346
Roflumilast18$2,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avadel CNS Pharmaceuticals, LLCLumryz$316$295,52622 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$14$155,980144 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$16$53,02046 claims
AstraZenecaBreztri Aerosphere$239$33,34840 claims
Arbor Pharmaceuticals, Inc.Horizant$15$23,18720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pinellas Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →